Clinical Management of Hepatitis C

Arun Jesudian, MD, FACG
Assistant Professor of Medicine
Director of Inpatient Liver Services
Weill Cornell Medicine
Disclosures

• No Disclosures
About Empire Liver Foundation and NYC Health Department

The Empire Liver Foundation is an association of NYS liver specialists dedicated to increasing community awareness of liver disease, providing education on liver disease to health care providers and patients and providing guidance to those who make policy decisions influencing the practice and science of liver disease.

- CME Grand Rounds
- CME Clinical Training Series
- Live Preceptorship
- Mentoring

www.empireliverfoundation.org

The New York City Health Department Viral Hepatitis Program conducts surveillance and develops and implements programs to build capacity to prevent, manage and treat hepatitis B and C in New York City.

- Surveillance
- Community Coalitions
- Navigation Programs
- Clinical Practice Facilitation
- Training

www.HepFree.NYC
Newly Reported Hepatitis C Based on NYC Neighborhoods
Newly Reported Chronic HCV in Brooklyn, 2019

Brooklyn:
• Highest number of new cases of chronic hep C in the five boroughs
• Had 1,130 (25.5%) newly reported HCV cases in 2019

Brighton Beach (BK19) neighborhood tabulation area (NTA)
• Rate: 111.5 per 100,000 people (NYC rate: 54.9)

Source: NYC Health Department (2020)
Newly Reported Chronic HCV in The Bronx, 2019

The Bronx:
- Highest rate (76.1 per 100,000)* of newly reported chronic HCV
- Had 1,043 (23.6%) newly reported HCV cases in 2019

Rikers Island (BX98) neighborhood tabulation area (NTA):
- Rate: 364.9 newly reported cases per 100,000 people (NYC rate: 54.9)

*includes people in Rikers Island facilities

Source: NYC Health Department (2020)
Manhattan:
- Second highest rate (61.8 per 100,000) of newly reported cases of chronic HCV in the 5 boroughs
- Had 976 (22.1%) newly reported HCV cases in 2019

Hudson Yards-Chelsea-Flatiron-Union Square (MN13) neighborhood tabulation area (NTA) *:
- Rate: 179.4 per 100,000 people, (NYC rate: 54.9)

*Many people reporting an address in this neighborhood use Manhattan’s main post office address, which is often used by people without a permanent residence.

Source: NYC Health Department (2020)
Queens:
• Had 855 (19.3%) newly reported HCV cases in 2019

Springfield Gardens North (QN02) neighborhood tabulation area (NTA):
• Rate: 76.5 per 100,000 people (NYC rate: 54.9)
• One of the highest rates of young people (ages 3-29) newly reported with chronic hepatitis C

Source: NYC Health Department (2020)
Newly Reported Chronic HCV in Staten Island, 2019

Staten Island:
• Had 179 (4.0%) new cases

Old Town-Dongan Hills-South Beach (SI36) neighborhood tabulation area (NTA):
• Rate: 82.1 per 100,000 people (NYC rate: 54.9)

Source: NYC Health Department (2020)
Learning Objectives

By the end of this presentation, participants should be able to describe:

1. The epidemiology of hepatitis C (HCV) in the United States and in New York City (NYC)
2. CDC screening recommendations for HCV and the New York State (NYS) testing law
3. Key steps in pre-therapy assessment
4. Candidates for HCV treatment with direct acting antiviral therapy
5. Patients that require monitoring after treatment
1. Epidemiology, Screening and Diagnosis
2. Pre-Therapy Assessment
3. Treatment of HCV with Direct Acting Antivirals
4. Drug-Drug Interactions
5. Special Populations
6. Access to Direct Acting Antivirals
7. Resources
Epidemiology, Screening and Diagnosis
Introduction to HCV

- Estimated 2.4 million infected in the USA
- Estimated 91,000 infected in NYC\(^1\)
  - 40% undiagnosed
- Leading indication for liver transplantation
- Leading predisposing factor to development of hepatocellular carcinoma (HCC)

1. NYC Health Department (2020)
HCV is Underdiagnosed in the US

Prevalence = 2.4 million individuals

- 52% aware
- 37% receive treatment

Large reservoir of infected patients undiagnosed

HCV Incidence in the United States

Estimated total new HCV infections

www.hepatitis.c.uw.edu/go/screening-diagnosis/epidemiology-us/core-concept/all.
As derived from CDC data, 2017. Ryerson AB et al. MMWR 2020;69:399.
Estimated total new HCV infections

- 180-200,000 new cases per year in 1991
- 11,800 new cases in 2010
- 50,300 new cases in 2018

As derived from CDC data, 2017. Ryerson AB et al. MMWR 2020;69:399.
### The Opioid Epidemic in the United States

<table>
<thead>
<tr>
<th>Statistic</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.3 million Americans misuse prescription opioids each year</td>
<td></td>
</tr>
<tr>
<td>2.0 million Americans have an opioid use disorder</td>
<td></td>
</tr>
<tr>
<td>808,000 Americans use heroin each year</td>
<td></td>
</tr>
<tr>
<td>81,000 new heroin users each year</td>
<td></td>
</tr>
<tr>
<td>32,656 deaths from synthetic opioids each year</td>
<td></td>
</tr>
<tr>
<td>15,349 deaths from heroin each year</td>
<td></td>
</tr>
</tbody>
</table>

About 40 percent of opioid users are infected with HCV

Rising Incidence of HCV in Youth in the U.S.

Rising Incidence of HCV in Youth: Newly Reported Cases by Age in NYS, 2005 and 2015

Reported cases of hepatitis C infection in New York State (exclusive of NYC)

Number of Newly Reported HCV Cases in NYC By Age, 2019

Source: NYC Health Department (2020)
Care cascade for people in NYC with chronic hepatitis C recently reported (from July 1, 2014 to June 30, 2019) with a positive hepatitis C test, regardless of year of first report

Source: NYC Health Department (2020)
Transmission of HCV

- Sharing supplies for injection or intranasal drug use
- Transfusion of blood/blood products prior to 1992
- Needle stick injury in health care
- Sharing personal care items (straight razors)
- Being born to a mother who has HCV
- Tattoos, body piercing in unlicensed setting
- Sex with an infected person (blood exposure)
HCV Risk Factors

Risk factors (not mutually exclusive) for HCV infection of people ages 18–34 years newly reported with chronic HCV in NYC in 2019, interviewed through enhanced surveillance (n=496)

- Injection drug use: 57.5%
- Intranasal drug use: 40.1%
- History of homelessness: 37.7%
- MSM: 27.9%
- HIV: 16.6%
- Household contact: 11.9%
- History of incarceration: 10.1%
- Non-professional tattoo or body piercing: 7.3%
- Other*: 4.1%

*Other includes: transfusion or transplant before 1992 or outside of the U.S.; employed in the medical or dental field; and received dialysis

Source: NYC Health Department (2020)
Acute Infection

HCC 1%-4% per year

Decompensated Cirrhosis
5-yr survival rate 50%

Chronic Infection
75%-85%

Cirrhosis
10%-20% over 20 years

Asymptomatic Extrahepatic manifestations

Most Americans infected >35y
Additional impact of:
- Alcohol
- Obesity
- Older age

*Most have minimal symptoms

HCC

Natural History of HCV

Most have minimal symptoms

*Most have minimal symptoms
Extrahepatic Manifestations of HCV

**Strongly associated**
- Mixed cryoglobulinemia
- Sjögren (sicca) syndrome
- Lymphoproliferative disorders
- Porphyria cutanea tarda
- Neuropathy
- Membranoproliferative glomerulonephritis
- Cryoglobulinemic vasculitis

**Possibly associated**
- Corneal ulcers (Mooren ulcers)
- Thyroid disease
- Lichen planus
- Pulmonary fibrosis
- Type 2 diabetes
- Systemic vasculitis (polyarteritis nodosa, microscopic polyangiitis)
- Arthralgias, myalgias, inflammatory polyarthritis
- Autoimmune thrombocytopenia

2020 CDC Recommendations HCV Screening Among Adults in the US

1. **Universal Screening**
   Screen at least once in a lifetime for **all adults ≥18 years**
   (except in settings where HCV RNA-positivity is <0.1%)

2. **Pregnancy**
   Screening **all pregnant women during each pregnancy**
   (except in settings where HCV RNA-positivity is <0.1%)

3. **Exposure**
   One-time testing among people with recognized conditions or exposures
   (more info on [https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm](https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm)), regardless of age or setting prevalence

4. **Periodic testing**
   Routine periodic testing for people with on-going risk factors
Hepatitis C Virus Testing (Chapter 425 of the Laws of 2013)

This law requires a **hepatitis C virus screening test** to be offered to all patients **born between 1945 and 1965** who are receiving health services as a hospital **inpatient or receiving primary care services** and applies to physician, physician assistant, or nurse practitioner.

The law further requires that the health care provider refer a patient who receives a **positive screening test** to another provider to **receive confirmatory testing and follow-up care**.
How Do You Diagnose HCV?

1. **Hepatitis C Antibody (HCV Ab)**
   - **Negative (-)**: STOP here if no concern for acute infection or severe immunosuppression. If so, check HCV RNA.
   - **Positive (+)**:
     1. **Check HCV RNA (viral load)**
        - **Negative (-)**: These people are NOT chronically infected. Detectable HCV Ab with negative HCV RNA can occur with spontaneous clearance of infection (about 25% of people exposed to HCV will clear; verify HCV RNA negative in 4 to 6 months) or with treatment of HCV.
        - **Positive (+)**:
          - **Hepatitis C infection**
          - **Evaluation and referral**

---

**ICD-10 codes for HCV antibody testing:**

* **z11.5:** Screening for other viral disease
* **R74.0:** Nonspecific elevation of levels of transaminase and lactic acid dehydrogenase
### Medical Provider Responsibilities

#### Diagnosing and Confirming HCV

<table>
<thead>
<tr>
<th><strong>Screen all adults 18-79 years, including pregnant women</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>In March 2020, USPSTF expanded its recommendation for one-time HCV screening to include all asymptomatic adults ages 18-79 years, including pregnant women: <a href="https://jamanetwork.com/journals/jama/fullarticle/2762186">https://jamanetwork.com/journals/jama/fullarticle/2762186</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Use HCV antibody with reflex to RNA testing</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Since 2017, NYC Health Code requires labs to automatically perform HCV RNA confirmatory test on all positive antibody test for HCV</td>
</tr>
<tr>
<td>Since 2015, NYS Department of Health recommends reflex testing and provides resources for implementation: <a href="https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/providers/reflex_testing.htm">https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/providers/reflex_testing.htm</a></td>
</tr>
</tbody>
</table>
Recommendations For HCV Screening In Persons Less Than 18 Years Of Age

- One-time testing should be performed for all persons less than 18 years of age with behaviors, exposures or risk factors or circumstances associated with an increased risk of HCV exposure
Re-testing for Patients at Risk for HCV

- Periodic repeat HCV testing should be offered to all persons with behavioral, exposures or risk factors associated with HCV
- Annual HCV testing is recommended for all persons who inject drugs and for HIV-infected men who have unprotected sex with men

• 48 year old man with history of IVDU
• Asymptomatic
• Takes milk thistle, St Johns wort
• ALT 45, AST 65, platelet count 100,000
• HCV RNA 655,000
• Genotype 1a
• Fibroscan 23 kPa (F4)
Pre-Therapy Assessment
**Simplified Algorithm for Management of HCV Infection**

1. **Screening and diagnosis**
   - Universal screening optimal
   - Risk factors/age screening
   - HCV antibody test with reflex to PCR
   - Positive (+) PCR
   - **Active HCV infection**

2. **Pretreatment assessment and testing**
   - **Initial assessment**: physical exam, stigmata of cirrhosis, clinical and prior treatment history, extrahepatic manifestations
   - **Blood tests**: CBC, AST, ALT, bilirubin, albumin, creatinine; HBV, HIV, HAV; eGFR
   - **Platelets >150x10^9/L**
   - Platelets <150 refer to specialist

3. **Treatment and monitoring**
   - **Assess for potential DDI**
   - **Treatment with pan-genotypic therapy**: GLE/PIB or SOF/VEL
   - **Assessment of cure (SVR12)**
     - HCV RNA, ALT
   - Negative (-) HCV RNA
   - **Cured**
   - Refer to post-cure management

---

*Dieterich et al, Gastroenterology & Hepatology; volume 15, issue 5, supplement 3, May 2019*
## Acute HCV: Interpretation of Tests

<table>
<thead>
<tr>
<th>Test</th>
<th>Interpretation</th>
</tr>
</thead>
</table>
| **HCV Ab** | • Test may be negative during first 6 weeks after exposure  
• Seroconversion may be delayed or absent in immunosuppressed individuals  
• Presence of HCV Ab alone does not distinguish between acute and chronic infection |
| **HCV RNA** | • Viral fluctuations $> 1 \log_{10} \text{IU/ml}$ may indicate acute HCV infection  
• HCV RNA may be transiently negative during acute HCV infection  
• Presence of HCV RNA alone does not distinguish between acute and chronic infection |
| **ALT** | • Fluctuating ALT peaks suggests acute infection  
• ALT may be normal during acute HCV infection  
• ALT may be elevated due to other liver insults, such as ETOH use |
HCV Provider Responsibilities
Obtain Basic Blood Tests

- CBC, platelets
- Comprehensive metabolic profile
  - Renal function
  - Liver chemistries
    - Albumin
    - Total bilirubin
    - Alkaline phosphatase
    - Aspartate aminotransferase
    - Alanine aminotransferase
  - INR
- Viral studies
  - HIV Ab
  - HAV Ab (total, not IgM!)
  - HBcAb (total, not IgM!)
  - HBsAg
  - HBsAb (quantitative)
HCV Provider Responsibilities
Evaluate for Coexisting Liver Disease

History
- Heart disease
- Diabetes, obesity → NAFLD
- Alcohol abuse → alcoholic liver disease
- Family history of autoimmunity
  - Autoimmune hepatitis
  - Primary biliary cholangitis
  - Primary sclerosing cholangitis
- Family history of liver disease
  - Hereditary hemochromatosis
  - Alpha-1 antitrypsin deficiency

Labs
- Antinuclear antibody (ANA)
- Antismooth muscle antibody (ASMA)
- Anti mitochondrial Ab (AMA)
- Fe / TIBC / Ferritin
- [Ceruloplasmin]
- [Alpha-1 antitrypsin level & phenotype]
- Alpha fetoprotein

Imaging
- Ultrasound
**Pre-Therapy Assessment: Drug-Drug Interactions**

- **Very important element in pre-therapy assessment**
- List of prohibited drugs is relatively short
  - Varies depending on regimen chosen
- List of “potential interaction” drugs is longer
- Be alert for interactions with common drugs
  - Statins, proton pump inhibitors, birth control, amiodarone, digoxin
- No herbs! In particular, no St. John’s Wort
- Use online tools to help assess DDI’s

Patients rarely tell you all the pills they are taking!
Assess for Potential Drug-Drug Interactions

<table>
<thead>
<tr>
<th>Key DDI</th>
<th>SOF/VEL</th>
<th>GLE/PIB</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>anticonvulsants, rifampicin, efavirenz, St. John’s wort</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- amiodarone</td>
<td>- dabigatran</td>
</tr>
<tr>
<td></td>
<td>- proton pump inhibitors</td>
<td>- ethinyl estradiol-containing contraceptives</td>
</tr>
<tr>
<td></td>
<td>- statins</td>
<td>- atazanavir</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- darunavir</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ritonavir</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- statins</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- cyclosporine</td>
</tr>
</tbody>
</table>

| Common drugs without interactions | ARBs, methadone, buprenorphine, calcium channel blockers, lamotrigine, omeprazole, progestin-only contraceptives |

HCPs should consult prescribing information, their local pharmacist and/or online tools (eg, HEP Drug Interactions; [http://www.hep-druginteractions.org](http://www.hep-druginteractions.org)) to confirm interaction or lack of interaction for specific drugs within a class, as exceptions may exist.

Dieterich et al, Gastroenterology & Hepatology; volume 15, issue 5, supplement 3, May 2019
HIV/HCV Co-infection: Drug-Drug Interactions

- Need to assess carefully:
  - [www.hcvguidelines.org](http://www.hcvguidelines.org)
  - [www.aidsinfo.nih.gov](http://www.aidsinfo.nih.gov)
  - [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

- If antiretroviral switch needed, should be done in collaboration with HIV practitioner
Importance of Assessing Fibrosis

- Patients with bridging fibrosis (stage 3 fibrosis) or cirrhosis (stage 4 Fibrosis) need additional screening:
  - Esophageal Varices
  - Hepatocellular carcinoma

- Allows for selection of proper treatment plan and duration of therapy
  - Protease inhibitors should NOT be used in patients with Child Class B or C cirrhosis.
# Methods for Staging Fibrosis

<table>
<thead>
<tr>
<th>Method</th>
<th>Procedure</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indirect serum markers</td>
<td>APRI, FIB-4*</td>
<td>Noninvasive; inexpensive</td>
<td>Limited ability to differentiate intermediate stages of fibrosis</td>
</tr>
<tr>
<td>Direct markers</td>
<td>FibroSure, FibroTest, FibroMeter, FIBROspect II, and HepaScore</td>
<td>Noninvasive; easily accessible</td>
<td>Limited ability to differentiate intermediate stages of fibrosis</td>
</tr>
<tr>
<td>VCTE</td>
<td>Shear wave velocity</td>
<td>Noninvasive; assesses large volume of liver parenchyma</td>
<td>May be difficult to interpret in F2 and F3 liver disease; limited availability</td>
</tr>
<tr>
<td>Liver biopsy (rarely used)</td>
<td>Pathologic examination</td>
<td>Diagnostic standard; diagnoses concurrent liver disease</td>
<td>Invasive procedure; costly; sampling error</td>
</tr>
</tbody>
</table>

*See Hepatitis C online for the following: [APRI Calculator](#) and [FIB-4 Calculator](#)*
Non-invasive Formulae to Assess Fibrosis

**APRI**

\[
APRI = \frac{AST \text{ Level (U/L)}}{\text{AST (Upper Limit of Normal) (U/L)}} \times 100
\]

**FIB-4**

\[
FIB-4 = \frac{\text{Age (years)} \times \text{AST Level (U/L)}}{\text{Platelet Count (10^9/L)} \times \sqrt{\text{ALT (U/L)}}}
\]
Non-invasive Formulae to Assess Fibrosis

**Aspartate aminotransferase-to-platelet ratio index (APRI)**

<table>
<thead>
<tr>
<th>Value</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 0.5%</td>
<td>Low risk of advanced fibrosis (F3-F4)</td>
</tr>
<tr>
<td>Between 0.5 and 1.5</td>
<td>Intermediate risk of advanced fibrosis</td>
</tr>
<tr>
<td>&gt; 1.5%</td>
<td>High risk of advanced fibrosis</td>
</tr>
</tbody>
</table>

**Fibrosis-4 Index (FIB-4)**

<table>
<thead>
<tr>
<th>Value</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 1.45</td>
<td>Low risk of advanced fibrosis (F3-F4)</td>
</tr>
<tr>
<td>Between 1.45 and 3.25</td>
<td>Intermediate risk of advanced fibrosis</td>
</tr>
<tr>
<td>&gt; 3.25</td>
<td>High risk of advanced fibrosis</td>
</tr>
</tbody>
</table>
Treatment of HCV with Direct Acting Antivirals
Goals of Treatment for HCV

- Goal is sustained viral response (SVR) = cure
  - Undetectable virus at least 12 weeks after cessation of anti-viral therapy
- Treatment selection generally dictated by genotype but pangenotypic options are now available
- HCV SVR rates = HCV/HIV SVR rates
SVR (Cure) Associated with Decreased All-Cause Mortality

530 patients with advanced fibrosis, treated with interferon-based therapy, and followed for 8.4 (IQR 6.4-1.4) years

The New World of HCV Therapy

- Interferon-free therapy is here
  - Direct acting antivirals (DAAs) treatment are the standard of care
- Cure is an almost certain outcome

Patient assessment prior to therapy is important
All patients with chronic HCV infection, regardless of fibrosis stage, are considered candidates for antiviral therapy.
High SVR Rates Achieved Across Patient Types

**SOF/VEL 12 weeks**
- F0–F4 & CTP A:
  - GT 1: 98% (323/328)
  - GT 2: 99% (237/238)
  - GT 3: 95% (264/277)
  - GT 4: 100% (116/116)
  - GT 5: 97% (34/35)
  - GT 6: 100% (41/41)
- CTP B–C*:
  - 94% (82/87)
  + RBV

**GLE/PIB 8, 12 or 16 weeks†**
- GT 1: 98% (502/513)
- GT 2: 98% (228/232)
- GT 3: 96% (289/302)
- GT 4: 96% (65/68)
- GT 5: 100% (4/4)
- GT 6: 94% (16/17)

*Safety and efficacy of SOF/VEL has not been assessed in patients with CTP class C cirrhosis; †As approved in the Canadian Product Monograph. These are not head-to-head studies and direct comparisons cannot be made; CTP: Child–Turcotte–Pugh; GLE/PIB: glecaprevir/pibrentasvir; GT: genotype; RBV: ribavirin; SOF/VEL: sofosbuvir/velpatasvir;
### Classes of Medications Used for Treatment

<table>
<thead>
<tr>
<th>NS3-4A Protease Inhibitors (“previr”)**</th>
<th>NS5A Inhibitors (“asvir”)</th>
<th>NS5B Inhibitors: (“buvir”)</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glecaprevir</td>
<td>Ledipasvir</td>
<td>Sofosbuvir</td>
<td>Ribavirin</td>
</tr>
<tr>
<td>Grazoprevir</td>
<td>Pibrentasvir</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voxilaprevir</td>
<td>Velpatasvir</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

** cannot use in decompensated disease
## Combination Therapies

<table>
<thead>
<tr>
<th>Combination Therapies</th>
<th>Trade Name</th>
<th>GFR &lt; 30</th>
<th>Decompensated Cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glecaprevir/Pibrentasvir</td>
<td>GLE/PIB</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Ledipasvir/Sofosbuvir</td>
<td>LDV/SOF</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Sofosbuvir/Velpatasvir</td>
<td>SOF/VEL</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Sofosbuvir/Velpatasvir/Voxilaprevir</td>
<td>SOF/VEL/VOX</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

**Bold** = protease inhibitor
Test for HBV Before Initiating HCV DAA Therapy

**ESAL:** Patients commencing DAA-based treatment for hepatitis C should be tested for HBs antigen, anti-HBc antibodies and anti-HBs antibodies (B1)

**AASLD:** All patients initiating HCV DAA therapy should be assessed for HBV coinfection with HBsAg, anti-HBs, and anti-HBc (B1)

<table>
<thead>
<tr>
<th>HBsAg test result</th>
<th>Anti-HBc test result</th>
<th>Negative</th>
<th>Positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>No risk of HBV reactivation</td>
<td></td>
<td>Very low risk of HBV reactivation</td>
</tr>
<tr>
<td>Positive</td>
<td>Moderate risk of HBV reactivation (depending on HBV DNA)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Monitoring During DAA Therapy: Hepatitis B Reactivation Risk

- In patients who are hepatitis B virus (HBV) surface antigen (HBsAg) positive and have no detectable HBV DNA:
  - **Monitor for HBV reactivation** by performing aspartate aminotransferase (AST), ALT, and HBV DNA tests every 4 weeks during HCV treatment.

- In patients who are HBsAg positive and detectable HBV DNA:
  - Monitor or treat as clinically indicated

- Clinicians new to HCV treatment should consult an experienced HCV care provider for further evaluation of patients who develop detectable HBV DNA.

http://www.hivguidelines.org/hcv-infection/treatment-with-daa/#tab_0
If a woman becomes pregnant during therapy with any DAA regimen… the clinician should discuss with her the benefits and risks of using DAAs during pregnancy.
Special Considerations
Consult With An Expert

- Treatment of decompensated cirrhosis
- Treatment of renal disease
- HIV/HCV coinfection
- Active alcohol / drug use
- Monitoring for hepatocellular carcinoma after SVR in patients with bridging fibrosis or cirrhosis
HIV/HCV Co-infection Treatment

- HIV/HCV co-infected persons should be treated the same as persons without HIV infection
- Treatment courses
  - 12 weeks of pangenotypic therapy
    - Gelcaprevir/Pibrentasvir (GLE/PIB)
    - Sofosbuvir/Velpatasvir (SOF/VEL)
Substance Use and HCV Treatment

• Do NOT withhold HCV treatment solely due to current drug/alcohol use
• Offer suboxone
• Refer to methadone clinics
• Write a prescription for syringes
  – Refer to syringe exchanges (for new cookers, cotton, etc)
• Provide naloxone kit or prescription for naloxone
• Assess for alcohol use and encourage cessation/reduction
• Discuss harm reduction and reinfection
• Treat sexual or drug-using partner together
HCV and Hepatocellular Carcinoma (HCC)

- SVR decreases risk of HCC development but does not eliminate risk
- All HCV patients with bridging fibrosis and cirrhosis need HCC screening, even after SVR
- Recommended HCC screening:
  - Hepatic imaging every 6 months
  - AFP
Removal of HCV Medication Prior Authorization

• As of July 23rd the NYS Medicaid Drug Utilization Review Board (DURB) unanimously voted to recommend removal of prior authorizations for patients awaiting their first HCV DAA treatment for NYS Medicaid Managed Care plans.

Contact Empire Liver Foundation if interested in learning more on how to advocate for removal of Prior Authorizations for Medicare & commercial insurance plans.
Case Study

- 48 year old man with history of IVDU
- Asymptomatic
- Takes milk thistle, St Johns wort
- ALT 45, AST 65, platelet count 100,000
- HCV RNA 655,000
- Genotype 1a
- Fibroscan 23 kPa (F4)
Case Study: What Would You Do

• Provide counseling to avoid:
  – Milk thistle
  – St John’s wort

• Counsel to take with care:
  – Other OTC products

• He has cirrhosis
  – EGD to screen for varices
  – Ultrasound for HCC screening

• For HCV
  – Check hepatitis B serologies
  – Initiate anti-viral therapy
  – Monitor throughout treatment
Summary

- HCV is curable with readily available combination therapies
- Elimination will require a multifactorial approach to diagnose, link to care, treat and cure HCV
  - To eliminate HCV, we need to broaden our treater base
- The Simplified Algorithm provides a roadmap for non-specialists to treat
- Costs of treatments have come down drastically
- Risk of HCC in cured patients with cirrhosis is decreased but patients still need to be screened for life
- The biggest issue now is getting people tested and treated
- Patients with advanced disease should be referred to a liver specialist
Resources

- NYS HCV Clinical Consultation Hotline: (866) 637-2342

- HCV Referrals: www.nyc.gov/health/hepc
  - Free or low-cost care
  - Programs with supportive services

- www.HepFree.NYC
  - CME HCV Training
  - NYC Hep C Task Force and HepCX
Hepatitis clinical care can continue during COVID-19 via telemedicine

- Hep Free NYC Telehealth Capacity Building Webpage
Contact Us

For CMEs or educational opportunities, contact:

Meg Chappell, MPH
Program Manager
Empire Liver Foundation
megchappell@empireliverfoundation.org
www.empireliverfoundation.org

For questions about resources, contact:

Marie P Bresnahan, MPH
Director, Training, Policy and Administration
Viral Hepatitis Program
New York City Health Department
mbresnahan@health.nyc.gov
www.hepfree.nyc
# Hepatitis B Training Series

<table>
<thead>
<tr>
<th>Date &amp; Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 13, 2022 @ 4:30PM</td>
<td>Hepatitis B: Epidemiology, Screening and Prevention with Paul Gaglio, MD</td>
</tr>
<tr>
<td>January 20, 2022 @ 4:30PM</td>
<td>Hepatitis B Pre-Treatment Evaluation and Treatment Initiation with Lisa Ganjhu, DO</td>
</tr>
<tr>
<td>January 27, 2022 @ 4:30PM</td>
<td>Management of Hepatitis B and Treatment Monitoring with Harmi Kalia, DO</td>
</tr>
</tbody>
</table>